Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 08 09:32AM ET
1.11
Dollar change
+0.01
Percentage change
0.92
%
Index- P/E- EPS (ttm)-2.26 Insider Own35.03% Shs Outstand29.74M Perf Week2.79%
Market Cap33.13M Forward P/E- EPS next Y-1.93 Insider Trans-16.23% Shs Float19.39M Perf Month6.74%
Income-64.66M PEG- EPS next Q-0.45 Inst Own49.49% Short Float0.72% Perf Quarter7.78%
Sales0.00M P/S- EPS this Y30.93% Inst Trans-27.04% Short Ratio0.23 Perf Half Y-54.13%
Book/sh3.30 P/B0.34 EPS next Y-1.98% ROA-62.35% Short Interest0.14M Perf Year-92.72%
Cash/sh3.50 P/C0.32 EPS next 5Y- ROE-69.48% 52W Range0.87 - 22.22 Perf YTD-94.58%
Dividend Est.- P/FCF- EPS past 5Y-73.03% ROI-65.74% 52W High-95.00% Beta-0.21
Dividend TTM- Quick Ratio10.61 Sales past 5Y0.00% Gross Margin- 52W Low27.60% ATR (14)0.03
Dividend Ex-DateApr 12, 2018 Current Ratio10.61 EPS Y/Y TTM19.09% Oper. Margin0.00% RSI (14)56.71 Volatility1.50% 2.90%
Employees41 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price2.67
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q40.29% Payout- Rel Volume0.11 Prev Close1.10
Sales Surprise- EPS Surprise20.79% Sales Q/Q- EarningsAug 13 AMC Avg Volume597.49K Price1.11
SMA203.07% SMA504.58% SMA200-64.09% Trades Volume4,165 Change0.92%
Date Action Analyst Rating Change Price Target Change
Aug-09-24Downgrade Leerink Partners Outperform → Market Perform $5 → $1
Aug-09-24Downgrade Evercore ISI In-line → Underperform
Jul-03-24Upgrade Leerink Partners Market Perform → Outperform $5
Apr-02-24Upgrade JMP Securities Mkt Perform → Mkt Outperform $6
Feb-13-24Downgrade Leerink Partners Outperform → Market Perform $23 → $7
Feb-12-24Downgrade Oppenheimer Outperform → Perform
Feb-12-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-12-24Downgrade Evercore ISI Outperform → In-line $25 → $7
Jan-04-24Initiated JMP Securities Mkt Outperform $30
Jul-18-22Resumed Oppenheimer Outperform $22
Oct-17-24 07:00AM
Aug-28-24 04:00PM
Aug-19-24 10:29AM
Aug-16-24 07:00AM
Aug-13-24 04:01PM
12:15PM Loading…
Aug-09-24 12:15PM
09:33AM
Aug-08-24 04:30PM
Jul-03-24 09:50AM
May-21-24 09:35AM
May-14-24 10:55PM
04:01PM
Mar-28-24 11:53PM
04:10PM
Mar-22-24 07:00AM
04:21AM Loading…
Feb-22-24 04:21AM
Feb-12-24 10:03AM
07:04AM
06:54AM
06:45AM
Jan-30-24 04:10PM
Jan-12-24 03:02AM
Jan-10-24 08:50AM
Nov-09-23 04:05PM
Nov-06-23 08:50AM
07:00AM
Oct-18-23 07:00AM
Oct-11-23 12:01AM
Sep-27-23 09:40AM
Sep-26-23 07:00AM
07:00AM Loading…
Sep-13-23 07:00AM
Sep-11-23 09:40AM
Aug-15-23 10:42PM
Aug-10-23 04:10PM
Jun-14-23 08:55AM
May-25-23 04:10PM
May-18-23 07:00AM
May-11-23 04:10PM
May-09-23 06:05AM
May-01-23 07:00AM
Mar-29-23 04:01PM
Feb-28-23 04:10PM
Jan-31-23 04:10PM
Dec-04-22 08:40AM
Nov-09-22 04:05PM
Nov-02-22 04:10PM
Oct-19-22 08:00AM
Oct-06-22 07:00AM
Sep-29-22 07:00AM
Aug-29-22 07:00AM
Aug-11-22 04:10PM
Aug-08-22 11:42AM
Jul-01-22 10:39AM
Jun-29-22 07:00AM
Jun-27-22 09:19AM
May-10-22 04:10PM
May-09-22 07:00AM
Apr-18-22 09:30AM
Mar-28-22 10:33AM
Mar-25-22 04:40PM
03:06PM
Mar-24-22 10:32PM
02:11PM
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA Capital Healthcare Fund LPAffiliateAug 15 '24Proposed Sale1.001,699,9981,699,999Aug 15 05:39 PM
RA Capital Nexus Fund II, L.P.AffiliateAug 15 '24Proposed Sale1.02299,999305,998Aug 15 05:34 PM
Leonard Braden Michael10% OwnerAug 14 '24Buy1.041,500,0001,560,0005,749,432Aug 14 08:24 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerAug 09 '24Sale1.083,525,0943,807,102300,853Aug 13 05:03 PM
Zakrzewski Joseph SDirectorJan 18 '24Sale19.11100,0001,911,410405,880Jan 19 07:32 PM
Aziz KabeerDirectorJan 16 '24Sale19.65100,0001,965,000377,542Jan 18 06:19 PM
Adjuvant Global Health Technol10% OwnerJan 16 '24Sale19.6584,0931,652,4271,995,958Jan 18 06:18 PM
Adjuvant Global Health Technol10% OwnerJan 16 '24Sale19.6515,907312,573377,542Jan 18 06:18 PM
Readnour Robin ShaneDirectorJan 12 '24Sale21.911,42531,229414,788Jan 17 05:03 PM
Readnour Robin ShaneDirectorJan 10 '24Sale21.933,66980,443415,494Jan 12 05:08 PM
Krause Kevin MichaelChief Strategy OfficerJan 09 '24Option Exercise4.597,41734,0159,331Jan 11 07:59 PM
Krause Kevin MichaelChief Strategy OfficerJan 09 '24Sale20.147,417149,3671,914Jan 11 07:59 PM
Krause Kevin MichaelChief Strategy OfficerJan 02 '24Option Exercise0.422,5831,0854,497Jan 04 06:06 PM
Krause Kevin MichaelChief Strategy OfficerJan 02 '24Sale20.122,58351,9671,914Jan 04 06:06 PM
Easom EricChief Executive OfficerJan 02 '24Sale20.092,77755,8022,130Jan 04 06:05 PM
Adjuvant Global Health Technol10% OwnerNov 14 '23Sale16.151,52224,5742,080,051Nov 16 06:59 PM
Adjuvant Global Health Technol10% OwnerNov 14 '23Sale16.152884,650393,449Nov 16 06:59 PM
Aziz KabeerDirectorNov 14 '23Sale16.151,81029,224393,449Nov 16 06:57 PM